Worldwide Clinical Trials partners with Datavant for real-world data pilot study

A group of executives work together to solve a puzzle
The two companies plan to build a single, de-identified data set layering EHRs, claims and clinical trial results on top of wearable devices, socioeconomic information and behavioral data. (Getty/ALotOfPeople)

Worldwide Clinical Trials and Datavant have partnered to explore the reasons clinical trials in neurodegenerative diseases fail, and how big data tactics can improve prolonged study monitoring and conduct.

The two companies plan to build a single, de-identified data set comprised of electronic health records, insurance claims and diagnostics—all linked to more nontraditional sources, including measurements from wearable devices, as well as socioeconomic and behavioral data.

And by layering on clinical trial data in a planned pilot study, the collaboration hopes to address the stubborn obstacles to conducting research studies in the field, such as slow recruitment, low patient engagement and compliance and inflexible protocol design.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Datavant recently acquired Universal Patient Key and its HIPAA-compliant de-identification technology. UPK’s platform turns protected health information into encrypted, site-specific tokens that Datavant can use to drive its data linking. The Roivant startup, its first outside drug development, was unveiled after securing $1.1 billion in investments last year.

RELATED: Datavant integrates 150 data sets, teams with Duke, G3, Verge Genomics

Worldwide has been looking to expand its services in real-world data as well, acquiring Continuum Clinical’s Late Stage research practice earlier this year. The CRO said the acquisition will expand its observational research study capabilities and add pre- and postapproval services in health economics, patient-reported outcomes and patient registries.

Together, Worldwide and Datavant are focused on “the uncommon value” that big data and next-generation analytics can offer throughout the research process, said Peter Benton, president and COO of Worldwide Clinical Trials.

RELATED: Worldwide Clinical Trials expands real-world services with Continuum late-stage buy

Neurodegenerative diseases such as Parkinson’s, Alzheimer’s, Huntington’s disorders and ALS represent staggering annual costs to the U.S. healthcare system and economy. They typically take a slow and erratic clinical course, with subtle onsets—posing specific difficulties for drug discovery, development and research, the companies said.

“The challenges that continue to persist in neurodegenerative diseases highlight the need for novel and evolved approaches to understanding both disease mechanics and patient progression,” said Datavant co-founder and CEO Travis May.

Suggested Articles

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.